The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and
behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain …

A lzheimer's disease (AD) is a neurodegenerative disorder characterized by loss of memory
and cognitive abilities, and the appearance of amyloid plaques composed of the amyloid‐β …

The therapeutic arsenal for the treatment of Alzheimer's disease (AD) remains confined to a
group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to …

Acetylcholinesterase (AChE; EC 3.1. 1.7) plays a crucial role in the rapid hydrolysis of the
neurotransmitter acetylcholine, in the central and peripheral nervous system and might also …

A combination of tacrine and tryptophan led to the development of a new family of
heterodimers as multi-target agents with potential to treat Alzheimer's disease. Based on the …

Mild cognitive impairment (MCI) is a modifiable risk factor in progression of several diseases
including dementia and type 2 diabetes. If cognitive impairments are not reversed at an early …

In the past several years, we postulated that the loss of Wnt signaling was implicated in the
pathology of Alzheimer's disease (AD). Since then, our lab and other groups have confirmed …

Alzheimer's disease (AD) is a slowly progressive neurodegenerative disease
conceptualized as a continuous process, ranging from mild cognitive impairment (MCI), to …

The molecular pathogenesis of Alzheimer's disease (AD) involves the participation of the
amyloid-β-peptide (Aβ), which plays a critical role in the neurodegeneration that triggers the …

Tacrine–melatonin hybrids are potential multifunctional drugs for Alzheimer's disease that
may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid …